RANZCP homepage
Date
3 May 2024
Location
Menzies AuditoriumRoyal Darwin Hospital, 105 Rocklands Drive
Tiwi, NT 0810
Delivery
HybridNT Branch, and NT PHN are partnering up again and would like to welcome Professor Mark Bellgrove who will present.
State-of-the-art in Attention Deficit Hyperactivity Disorders (ADHD) - genes, cognition and brain networks
Presenters
Professor Mark Bellgrove
Mark Bellgrove is Professor in Cognitive Neuroscience in the School of Psychological Sciences, at Monash University, where he leads a multidisciplinary team studying the biological basis of attention and cognitive control in both health and disorder (eg ADHD). His group has made significant progress in defining the molecular genetic architecture and neurochemical drivers of attention and cognitive control.
Professor Bellgrove has been at the forefront of international efforts to identify objective and quantifiable indices of genetic risk, termed endophenotypes, for ADHD. His early work identified reliable linkages between catecholamine risk genes for ADHD and distinct neurocognitive profiles. This work was published in high impact journals, has attracted high citations and continues to be influential in shaping the way the field approaches the issue of clinical and aetiological heterogeneity that besets psychiatric genetics. With papers in top-tier journals including Molecular Psychiatry, Nature Neuroscience, Nature Human Behaviour, Neuron and the Journal of Neuroscience, Professor Bellgrove is a recognized international expert on the molecular genetics of attention and attention deficit. The research achievements of Professor Bellgrove have been recognized with awards from NARSAD (USA), the Academy of Social Sciences in Australia and Biological Psychiatry Australia. In 2021 he was elected to Fellowship of the Academy of Social Sciences in Australia (FASSA). In 2021 he was also recognised as Supervisor of the Year within the Faculty of Medicine, Nursing and Health Sciences at Monash University.
His programme of research is funded by both the National Health and Medical Research Council (NHMRC), the Medical Research Future Fund (MRFF) and Australian Research Council (ARC). He currently holds an NHMRC Investigator Grant (Level 2). In 2016 Professor Bellgrove founded the Australian ADHD Professionals Association (AADPA), an interdisciplinary group devoted to advancing evidence-based diagnosis and treatment of ADHD in Australia. He led the development of the Australian evidence-based clinical practice guideline for ADHD, which was approved by the NHMRC in October 2022. With international colleagues he has recently published a state-of-the-art primer on Attention Deficit Hyperactivity Disorder (ADHD)
Mark Bellgrove is Professor in Cognitive Neuroscience in the School of Psychological Sciences, at Monash University, where he leads a multidisciplinary team studying the biological basis of attention and cognitive control in both health and disorder (eg ADHD). His group has made significant progress in defining the molecular genetic architecture and neurochemical drivers of attention and cognitive control.
Professor Bellgrove has been at the forefront of international efforts to identify objective and quantifiable indices of genetic risk, termed endophenotypes, for ADHD. His early work identified reliable linkages between catecholamine risk genes for ADHD and distinct neurocognitive profiles. This work was published in high impact journals, has attracted high citations and continues to be influential in shaping the way the field approaches the issue of clinical and aetiological heterogeneity that besets psychiatric genetics. With papers in top-tier journals including Molecular Psychiatry, Nature Neuroscience, Nature Human Behaviour, Neuron and the Journal of Neuroscience, Professor Bellgrove is a recognized international expert on the molecular genetics of attention and attention deficit. The research achievements of Professor Bellgrove have been recognized with awards from NARSAD (USA), the Academy of Social Sciences in Australia and Biological Psychiatry Australia. In 2021 he was elected to Fellowship of the Academy of Social Sciences in Australia (FASSA). In 2021 he was also recognised as Supervisor of the Year within the Faculty of Medicine, Nursing and Health Sciences at Monash University.
His programme of research is funded by both the National Health and Medical Research Council (NHMRC), the Medical Research Future Fund (MRFF) and Australian Research Council (ARC). He currently holds an NHMRC Investigator Grant (Level 2). In 2016 Professor Bellgrove founded the Australian ADHD Professionals Association (AADPA), an interdisciplinary group devoted to advancing evidence-based diagnosis and treatment of ADHD in Australia. He led the development of the Australian evidence-based clinical practice guideline for ADHD, which was approved by the NHMRC in October 2022. With international colleagues he has recently published a state-of-the-art primer on Attention Deficit Hyperactivity Disorder (ADHD)
Online access
Webinar attendees will be sent the Teams prior to the event. Confirmation of Start time for the webinar will also be sent with the link.
Support
Contact
Please contact Lisa Meredith if you have any questions.
02 6229 2800
Cancellation policy
There is no cancellation policy as this is a free event. Please email ranzcp.nt@ranzcp.org if you do not plan to attend as there are limited numbers.
Delegate cancellation - Medical
The health and safety of conference attendees is our highest priority. The RANZCP is mindful of the health risks posed by COVID-19, and the importance of following official medical advice with respect to social distancing, practicing good hygiene and staying at home when unwell. The RANZCP requests that any delegate who is feeling unwell or has cold or flu like symptoms, or who may have been in contact with someone with COVID-19, not attend the conference.
If, on medical grounds, you are unable to attend the conference, you must cancel your attendance in writing by email to ranzcp.nt@ranzcp.org.
Conference cancellation
The RANZCP is monitoring the latest health advice from both the Department of Health (Australia) and the Northern Territory Government, and we ask that all delegates do the same. If we are required to make any changes or cancellations to our conference due to government restrictions in relation to COVID-19, delegates will be notified by email.
COVID safety
The RANZCP is committed to the health and safety of all members, meeting participants and maintaining a safe system of work for staff. Whilst not mandatory, high-quality face masks and pre-arrival testing (Rapid Antigen Tests) are encouraged to ensure the health and wellbeing of colleagues and staff are maintained. Should you wish to discuss your personal circumstances further, please contact Branch Coordinator at ranzcp.nt@ranzcp.org.
All participants at the conference will be required to comply with the COVID Safety Guidelines and protocols in place with the venue/s and the conference which will be aligned and compliant with all relevant Commonwealth and state government health advice at that time. By registering for this event, the RANZCP reserves the right to provide your contact details to authorities for the purposes of contact tracing and any other relevant government requirements.
Details of the protocols and requirements will be available on the website and all registrants will be bound by these requirements. The RANZCP reserves the right to update the COVID protocols to ensure the health and safety of participants, including but not limited to event entry requirements. Participants may be excluded if they do not comply with the requirements of the COVID Safety Guidelines and protocols.
